

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 21, 2019**

---

**OVID THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(state or other jurisdiction  
of incorporation)

**001-38085**  
(Commission  
File Number)

**46-5270895**  
(I.R.S. Employer  
Identification No.)

**1460 Broadway, Suite 15044**  
**New York, New York**  
(Address of principal executive offices)

**10036**  
(Zip Code)

**Registrant's telephone number, including area code: (646) 661-7661**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 8.01. Other Events.**

On March 21, 2019, Ovid Therapeutics Inc. (the “Company”) issued a Press Release announcing the appointment of Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary. Mr. Perone is succeeding Ana Ward who will be leaving the Company.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibit

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release, dated March 21, 2019</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OID THERAPEUTICS INC.**

By: /s/ Ana C. Ward  
Ana C. Ward  
Senior Vice President, General Counsel

Dated: March 21, 2019



## **Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary**

**NEW YORK – March 21, 2019** - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced the appointment of Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary. Mr. Perone is succeeding Ana Ward who will be leaving the Company.

“We are delighted to welcome Tom to Ovid,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “2019 will be an extremely active year as we advance into the NEPTUNE Phase 3 pivotal study of OV101 in Angelman syndrome, report top-line results from our Phase 2 ROCKET trial for OV101 in Fragile X syndrome and progress our Phase 2 pipeline in developmental and epileptic encephalopathies for OV935. The experience and insight Tom brings from serving at and helping to grow a premier biopharmaceutical company will be invaluable to Ovid as we take these important next steps. Lastly, I also want to thank Ana Ward for her contributions to Ovid and wish her well in the next phase of her career.”

Mr. Perone is joining Ovid with more than 20 years of legal and pharmaceutical experience. He was most recently at Celgene Corporation where for 12 years he held positions of increasing levels of responsibility most recently, as Vice President, Assistant General Counsel and Assistant Corporate Secretary. While at Celgene, Mr. Perone was responsible for corporate securities matters, transactional matters including mergers, acquisitions and licensing opportunities and contracting matters for North and South America including supporting Celgene’s clinical, manufacturing and commercial teams. Prior to joining Celgene, he was a senior legal director at ImClone Systems Inc. and began his legal career as an associate attorney at Proskauer Rose LLC in New York City. Mr. Perone received a B.Sc. in mechanical engineering from Rutgers University, an M.B.A. from Fairleigh Dickinson University and a JD with honors from Seton Hall University School of Law.

“I am excited to be joining the leadership team at Ovid at this important time for the Company as it prepares to progress its pipeline products into pivotal clinical trials,” said Mr. Perone. “I am thrilled to have the opportunity to contribute to the growth and success of Ovid and to advance Ovid’s pipeline products which have the potential to have a positive impact on the lives of patients in need.”

### **About Ovid Therapeutics**

---

Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company's lead investigational medicine, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK-935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit <http://www.ovidrx.com/>.

### **Forward-Looking Statements**

This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding advancing Ovid's product candidates, progress, timing, scope and results of clinical trials for Ovid's product candidates, and the reporting of clinical data regarding Ovid's product candidates. You can identify forward-looking statements because they contain words such as "will," "believes" and "expects." Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid's filings with the Securities and Exchange Commission under the caption "Risk Factors". Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

### **Contacts**

#### **Investors:**

Investor Relations & Public Relations  
Ovid Therapeutics Inc.  
[irpr@ovidrx.com](mailto:irpr@ovidrx.com)

Alex Gray  
Burns McClellan, Inc.  
[agray@burnsmc.com](mailto:agray@burnsmc.com)  
(212) 213-0006

#### **Media:**

Jerica Pitts  
W2Opure  
[jpitts@purecommunications.com](mailto:jpitts@purecommunications.com)  
(312) 858-3469